Study on Effect of Lamivudine in the Treatment of 36 Patients with CHB and HBV Carrier
10.3870/j.issn.1004-0781.2001.06.033
- VernacularTitle:拉米夫定治疗慢性乙肝及乙肝病毒携带者36例
- Author:
Yubao LIAN
;
Chunxiao WU
;
Guixiang ZHOU
- Publication Type:Journal Article
- From:
Herald of Medicine
2001;(6):365-366
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To Study the efficacy and satety of lamivudine in the treatment of CHB and HBV carrier. Methods:All patients were divided into three groups. 21 patients with CHB were classified CHB test group(namely groupⅠ), 16 HBV carries were classified ASC test group(namely Group Ⅱ), 40 patients with CHB were CHB controlled group(namely controlled group). Both group Ⅰ and group Ⅱ received lamivudine, group Ⅰ was added protecting liver therapy. The controlled group only received protecting liver therapy. The treatment courses of three groups were one year. Results:The effective rates of group Ⅰ and group Ⅱ were higher than the controlled group in turning into negative HBeAg and HBV-DNA, both the negative-turning rate of liver functions and hepatic serology target declining fibrosis in group Ⅰ was more significant than the controlled group without severe side effect. Conclusion:Lamivudin is efficient and safe medicine in the treatment of CHB and HBV carrier.
